• No se han encontrado resultados

TítuloValidation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis

N/A
N/A
Protected

Academic year: 2020

Share "TítuloValidation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis"

Copied!
13
0
0

Texto completo

Loading

Figure

Table 1. Clinical characteristics of the 566 patients with RA.
Table 2. Characteristics of the patients associated with ΔDAS28 at 6 months in either univariate or multivariate regression.
Table 3. Results of the linear regression between the studied SNPs and ΔDAS28 at 3, 6 and 12 months of treatment a .
Table 5. Direct comparison of results for the same outcomes in the current and previous studies

Referencias

Documento similar

• Validation of the relational resilience construct.. central strategy of crisis response in the fam- ily businesses under study. Following Hanelt et al. 2), we define

low risk; IR: intermediate risk; HiR: high risk; GS: Gleason score; HiP: high PORTOS score; DM: distant metastasis; PCSM: prostate cancer specific mortality; BF: biochemical failure;

Therefore, we performed a candidate gene study to investigate single-nucleotide polymorphisms (SNPs) that can predict the response to anti-TNF drugs in Caucasian

In JIVET the high percentage of small antral follicles makes oocyte collection by follicular aspiration difficult (reviewed by Paramio & Izquierdo 50 ).

Although we did not observe a significant association of CD40-CD154 gene variants with the development of CV events, an ANCOVA model adjusted for sex, age at the time of

Through looking at the link between the chemical structure and the activity, our study proves that changes made to natural macamides at the level of the alkyl chain, the

The analysis of low-frequency genetic variants mapping to the TNF signaling pathway using the SKAT-O test showed that the damaging burden is different between anti-TNF

Figure 4. Overview of the mutations identified in PRORADIUM cohort. A) Bar graph representing the frequency of mutational status described as a benign, pathogenic